Satralizumab Sustains Proptosis Improvement in 85% of Responders With Thyroid Eye Disease at 48 Weeks
Satralizumab (Enspryng) maintained reductions in eye bulging for roughly 85% of responders with thyroid eye disease through 48 weeks, according to pooled phase 3 data presented this week at the … Read More